|
|
|
|
|
|
|
10.11.25 - 16:36
|
The Best Canadian Stock You′ve Never Heard of (Fool)
|
|
|
Down over 90% from all-time highs, AbCellera Biologics is a Canadian stock with significant upside potential.
The post The Best Canadian Stock You've Never Heard of appeared first on The Motley Fool Canada....
|
|
|
10.11.25 - 15:03
|
AbCellera Appoints Dr. Stephen Quake to its Board of Directors (Business Wire)
|
|
|
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director.
Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications.
“We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “He brings a distinctive combination of scientific breadth, creativity, and interdisciplinarity that resonates with AbCellera's culture and strategy.”
Dr. Quake is currently the Lee Otterson Professor of Bioengineering and Professo...
|
|
|
|
|
|
|
06.11.25 - 22:12
|
AbCellera Reports Q3 2025 Business Results (Business Wire)
|
|
|
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“AbCellera successfully delivered on two corporate priorities this quarter by starting activities at our new clinical manufacturing facility and substantially completing our platform investments,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We ended the quarter with approximately $680 million dollars in available liquidity to execute on our strategy and will continue to prioritize advancing our two lead programs through Phase 1 clinical studies and building our pipeline.”
Q3 2025 Business Summary
Generated a net loss of $57.1 million, compared to a net loss of $51.1 million in 2024.
Expanded the leadership team with the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer.
ABCL635 and ABCL575 continue to progress through Phase...
|
|
|
|
|
29.09.25 - 22:06
|
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
|
|
|
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com. Contacts
Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116...
|
|
|
|
|
19.09.25 - 00:48
|
Life Sciences BC 2025-26 Board of Directors Announcement (Business Wire)
|
|
|
VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences BC (LSBC) is pleased to announce new and returning members to the Board of Directors following its Annual General Meeting (AGM) on September 17, 2025. The Board of Directors is comprised of seasoned leaders dedicated to driving forward the growth of the life sciences sector.
New and Returning Board Members and Observers
LSBC welcomes Christina Zacharuk, CEO of Research Universities' Council of British Columbia, and Sandra Wong, Senior Manager, Access and Government Affairs of Pfizer Canada, who were each elected to three-year terms.
Anne Stevens, VP Business Development of AbCellera, Michael Martin, Global Biopharmaceutical Executive, and Suzanne Gill, President & CEO of Genome British Columbia, were each re-elected to three-year terms.
At the Board Meeting following the AGM, Hector MacKay-Dunn, KC, Joseph Garcia, and Roger Kuypers received renewed one-year appointments as Board Observers.
The full slate of LSBC's Board of Directors is listed b...
|
|
|
10.09.25 - 15:09
|
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer (Business Wire)
|
|
|
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist, brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization across a diverse range of indications and therapeutic modalities, including oncology, neuroscience, rare diseases, gene therapy, and cell therapy. As Chief Medical Officer, Dr. Noonberg, will leverage her clinical development background to advance AbCellera's pipeline of antibody-based therapeutics.
“We are pleased to welcome Sarah as AbCellera's first Chief Medical Officer,” said Carl Hansen, PhD, founder and CEO of AbCellera. “With more than 20 years of experience in clinical development, Sarah brings deep expertise and proven operational and leadership strength that will be invaluable as we continue to build and advance our clin...
|
|
|
|
|
|
|
|
|
|
|
07.07.25 - 22:09
|
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
|
|
|
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development pr...
|
|
|
|
|
|
|
10.05.25 - 01:36
|
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting (Business Wire)
|
|
|
ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD)
In preclinical studies, ABCL575 shows potent inhibition of inflammatory pathways, favorable in vivo pharmacokinetics (PK), and potential for less frequent dosing compared to a clinical benchmark
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California.
AbCellera's presentation, which is available for viewing here, describes key properties of ABCL575, including:
Potent functional activity that is equivalent to the most advanced clinical benchmark, with inhibition of OX40L signalling and T-cell activation in vitro and significant reduction of Th2 cytokines in vivo.
Modified Fc domain that supports Fc-silencing and half-life extension, wi...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
